Gamaze MF

Indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes who are already treated with a combination of Gliclazide (Gamaze MF) and Metformin (Gamaze MF) or whose diabetes is not adequately controlled with Metformin (Gamaze MF) alone, or for those patients who have initially responded to Gliclazide (Gamaze MF) alone and require additional glycaemic control.

1-2 tab once or bid. Max: 4 tab/day.

1. Known hypersensitivity to Gliclazide (Gamaze MF) or Metformin (Gamaze MF) or any components of Gamaze MF

2. Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ³ 1.5 mg/dL [males], ³ 1.4 mg/dL [females] or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia

3. Congestive heart failure requiring pharmacologic treatment

4. Known hypersensitivity to this product or any of its components.

5. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin

6.

Patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function.

May decrease Metformin (Gamaze MF) elimination w/ cationic drugs eg amiloride, cimetidine, digoxin, morphine, procainamide, quinidine, ranitidine, vancomycin. Increased hypoglycemic effect of Gliclazide (Gamaze MF) w/ miconazole & phenylbutazone. Increased Metformin (Gamaze MF) plasma C_max & AUC w/ furosemide. Block absorption of vit B₁₂. Enhance Metformin (Gamaze MF) absorption w/ nifedipine. Salicylates & thiazide diuretics.

GI disturbances, skin reaction, leucopenia, thrombocytopenia, agranulocytosis, haemolytic anaemia, cholestatic jaundice, vomiting, diarrhoea, gastritis, increased transaminases.